with chronic phase CML. [32] These hematologic "remissions" are characterized by persistence of Ph-positive cells in the marrow, with inevitable progression to blast crisis. Suppression of ...

In its natural history, CML is usually diagnosed in chronic phase (CP) and then progresses through an accelerated phase to a nearly invariably fatal blast crisis (BC). The mechanisms of ...

He explained that CML progresses through three distinct phases: chronic, accelerated, and blast. The chronic phase constitutes about 90% of CML cases. “This phase can extend over several years ...

Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has ...

The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to ...

Dasatinib Tablets US market size was approximately $1.8 billion for the 12 months ended February 2025, based on industry data ...

Aurobindo Pharma's shares rose nearly 3% after its subsidiary, Eugia Pharma, received USFDA approval to market Dasatinib ...

The structural basis for imatinib resistance in chronic myeloid leukaemia (CML) involves the emergence of imatinib-resistant BCR-ABL point mutations; mutations are usually those that impair drug ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine ...

Hyderabad: Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Eugia PharmaSpecialities Limited, has ...

[109] No standard therapy has been demonstrated to stem the progression to blast crisis ... Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published ...